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Abstract
Objective To determine the availability of data on overall survival and
quality of life benefits of cancer drugs approved in Europe.
Design Retrospective cohort study.
Setting Publicly accessible regulatory and scientific reports on cancer
approvals by the European Medicines Agency (EMA) from 2009 to 2013.
Main outcome measures Pivotal and postmarketing trials of cancer
drugs according to their design features (randomisation, crossover,
blinding), comparators, and endpoints. Availability and magnitude of
benefit on overall survival or quality of life determined at time of approval
and after market entry. Validated European Society for Medical Oncology
Magnitude of Clinical Benefit Scale (ESMO-MCBS) used to assess the
clinical value of the reported gains in published studies of cancer drugs.
Results From 2009 to 2013, the EMA approved the use of 48 cancer
drugs for 68 indications. Of these, eight indications (12%) were approved
on the basis of a single arm study. At the time of market approval, there
was significant prolongation of survival in 24 of the 68 (35%). The
magnitude of the benefit on overall survival ranged from 1.0 to 5.8 months
(median 2.7 months). At the time of market approval, there was an
improvement in quality of life in seven of 68 indications (10%). Out of
44 indications for which there was no evidence of a survival gain at the
time of market authorisation, in the subsequent postmarketing period
there was evidence for extension of life in three (7%) and reported benefit
on quality of life in five (11%). Of the 68 cancer indications with EMA
approval, and with a median of 5.4 years’ follow-up (minimum 3.3 years,
maximum 8.1 years), only 35 (51%) had shown a significant improvement
in survival or quality of life, while 33 (49%) remained uncertain. Of 23
indications associated with a survival benefit that could be scored with
the ESMO-MCBS tool, the benefit was judged to be clinically meaningful
in less than half (11/23, 48%).
Conclusions This systematic evaluation of oncology approvals by the
EMA in 2009-13 shows that most drugs entered the market without
evidence of benefit on survival or quality of life. At a minimum of 3.3
years after market entry, there was still no conclusive evidence that
these drugs either extended or improved life for most cancer indications.
When there were survival gains over existing treatment options or
placebo, they were often marginal.
Introduction
Before new prescription medicines are allowed onto the market,
they must be tested in studies and show, to the satisfaction of
drug regulatory agencies, that their benefits outweigh the harms
of drug toxicity. The most informative and valuable studies are
those providing robust evidence from well designed randomised
controlled trials that a new drug has a significant effect on
outcomes that are important to patients and that the magnitude
of those effects, compared with other treatment options, are
clinically meaningful. Although the goal of cancer treatment is
to improve the quantity and quality of life,1-3 clinical trials
designed to gain regulatory approval for new drugs often
evaluate indirect or “surrogate” measures of drug efficacy. These
endpoints show that an agent has biological activity, but they
are not reliable surrogates for improved survival4-11 or quality
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of life4-13 in all settings, and two recent systematic reviews
suggest that the strength of association between surrogates in
cancer clinical trials and life extension is generally low.8 14
Moreover, there is growing concern that the benefits offered by
many new treatments for cancer—often discussed and promoted
as “breakthroughs”15-18—are marginal and might not be clinically
meaningful to patients, despite rapidly escalating costs.19-23
Consequently, there have been calls to raise the evidence bar
for market authorisation of new cancer drugs.15-26
No recent studies have systematically examined the evidence
base and magnitude of benefit for cancer drugs approved by the
European Medicines Agency (EMA).27-29 Available data from
the US show that only a small proportion of cancer treatments
approved by the US Food and Drug Administration (FDA)
unequivocally show benefits on survival or quality of life.30 The
applicability of this evidence to the European context, however,
is not clear. Recent FDA-EMA comparisons show differences
in regulatory decisions, route of approval, and availability of
cancer drugs that could have important implications for clinical
practice and patient safety.31-35 In particular, regulatory
provisions for expediting drug development and approval differ
between the US and the EU,32 with EU regulation being more
restrictive in scope.36 This could lead to divergent outcomes
between the two regions.
The proportion of cancer drugs approved by the EMA without
any demonstrable benefits on survival or quality of life is not
known. In addition, whether treatments approved without
evidence of benefit on survival are subsequently shown to
improve survival or quality of life in postmarketing studies has
not been characterised.
We sought to systematically evaluate the evidence base for all
new drugs and new indications for the treatment of solid tumours
and haematological malignancies approved by the EMA in the
five year period 2009-13. We determined the proportion of drugs
with demonstrable benefit on survival or quality of life over
available treatment options or placebo, both at time of approval
and in the postmarketing period. In addition, we used a validated
scale to evaluate the magnitude of benefit of drugs in our sample
showing a significant improvement on survival in the treatment
of solid cancers.
Methods
Cohort of cancer drugs approved by EMA
2009-13
We searched the publicly available EMA database of European
Public Assessment Reports using L01-04 ATC codes to identify
“antineoplastic and immunomodulating” agents for solid
tumours and haematological malignancies authorised from 1
January 2009 to 31 December 2013. Consistent with previous
research,30 our study period ended in 2013, which allowed
adequate time for the completion of randomised trials in the
postmarketing period. We excluded paediatric indications,
indications for the treatment of benign tumours, supportive
treatments, and generic products (fig A in appendix). Authorised
indications for each drug were identified by searching the EPAR
document “Procedural steps taken and scientific information
after authorisation.”
We distinguished between different types of regulatory approval.
A “first marketing authorisation” indicates that the drug is a
new active substance, approved onto the EU market for the first
time. An “extension” to a marketing authorisation is when a
marketed drug is approved for use in a new patient population,
new combination, new line of treatment, or new type of cancer.
By law, a “regular marketing authorisation” should be based on
comprehensive evidence of quality, safety, and efficacy.
“Conditional marketing authorisations” can be granted for drugs
intended to treat patients with seriously debilitating or life
threatening diseases and are expected to fulfil an unmet medical
need. Conditional approvals are granted on the basis of less
comprehensive data than required for a regular marketing
authorisation, and companies are required to generate additional
evidence in the postmarketing period.36 “Orphan drug”
designation is granted for the treatment of rare cancers. We also
categorised indications according to cancer site and stage of
disease (specifically whether treatments were to be used in a
curative or non-curative setting).
Data sources and search strategies
To determine the availability of evidence on overall survival
and quality of life gains at time of market approval for the drugs
in our cohort, we manually searched the EMA website to
identify the relevant European Public Assessment Reports
(EPARs). EPARs are official regulatory documents in the public
domain that summarise the evidence base for a new drug or new
indication and provide a justification for the EMA’s decision
to grant a marketing authorisation or extension to the marketing
authorisation. Clinical trial data supporting approval of each of
the unique indications were retrieved from the EPARs. We
included only data from those studies identified by the EMA as
the main, or “pivotal,” studies supporting approval.
To determine whether drugs that did not show any survival gain
at the time of approval were subsequently confirmed to improve
survival or quality of life in the postmarketing period, we
searched PubMed for randomised controlled trials reporting
these outcomes for the relevant indications. Our search strategy
included the drug name, approved indication, and search terms
for the endpoints of interest (overall survival or quality of life
or QoL or HRQoL) (fig B in appendix). We identified
randomised controlled trials using the Cochrane Collaboration
sensitivity and precision maximising search strategy for
identifying randomised trials.37 When possible, we cross checked
search results against the European Clinical Trials Database
(EudraCT) and the US National Library of Medicine database
of clinical trials (ClinicalTrials.gov). Our latest search was on
31 March 2017, which allowed for at least 3.3 years for the
completion and publication of clinical studies in the
postmarketing period (median 5.4 years, maximum 8.1 years).
For those drugs associated with an overall survival gain at the
time of approval or in the postmarketing period, we used the
European Society for Medical Oncology’s (ESMO) Magnitude
of Clinical Benefit Scale (ESMO-MCBS) to assess the clinical
value of these gains as reported in published studies.38 The
ESMO-MCBS scale is a tool for evaluating the clinical benefit
of new treatments for solid tumours to facilitate the presentation
of clear and unbiased statements regarding the relative clinical
benefit of new treatments.
Data extraction, outcome variables, and data
analysis
Three investigators (AP, EP, and EG) independently extracted
data on and descriptively analysed the following trial features:
characteristics of the participant population, study design
(randomisation, crossover from experimental to control group,
and blinding of investigators and participants), experimental
and control groups, enrolment, primary and secondary endpoints,
magnitude of benefit on survival and quality of life, and
narrative interpretation of the findings. We classified
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comparators as active (in trials comparing drugs A versus B),
add on (in trials comparing drugs A+B versus B alone), placebo,
or none. Investigators cross checked each other’s data extraction.
Difficulties or disagreements in interpretation were resolved by
discussion and consensus among the three lead investigators
(CD, HN, and AA). All data were also checked by the principal
investigator (CD).
We judged that a drug had shown a survival benefit in its
approved indication if, as reported in the EPAR or study
publication, overall survival was the primary or secondary
endpoint in a randomised controlled trial, and the difference in
survival between the experimental and control arms was
significant according to a prespecified statistical analysis. If an
analysis was described as “exploratory” we considered it to be
a post hoc analysis. Post hoc analyses (in which the hypotheses
being tested were not specified before examination of the data)
were accepted if the EMA specifically determined that these
analyses provided evidence of a survival benefit. If a published
study reporting results of a pivotal trial conflicted with the
EMA’s assessment or other information contained in an EPAR,
we made a determination consistent with the EPAR, unless the
published study reported an updated analysis.
We considered that a drug had shown a benefit on quality of
life in its approved indication when a significant difference was
reported for an item or subscale derived from a validated quality
of life instrument, even in the absence of a significant benefit
with respect to the global score.
Determination of ESMO-MCBS score
Our scoring was limited to drugs for solid tumours as the ESMO
scales are not intended for evaluation of drugs to treat
haematological malignancies.38 Two investigators (AA and CD)
independently graded individual trials based on published papers
that reported a significant difference in overall survival (as a
prespecified primary or secondary study endpoint) using the
most recent version of the ESMO-MCBS evaluation forms.39
There was complete agreement between the two investigators
in the scoring. As per the established ESMO methods, each
score was assigned based on the magnitude of the absolute
survival gain and the lower limit of the 95% confidence interval
of the hazard ratio, and only significant changes in toxicity or
quality of life parameters were used to modify the grades. Only
scores of A or B (for treatments of curative intent), or 5 or 4
(for treatments used in the non-curative/palliative setting) are
defined as clinically meaningful according to the ESMO
framework.
Patient involvement
No patients were involved in setting the research question or
the outcome measures, nor were they involved in developing
plans for design or implementation of the study. No patients
were asked to advise on interpretation or writing up of results.
There are no plans to disseminate the results of the research to
study participants or the relevant patient community.
Results
From 2009 to 2013, the EMA approved use of 48 oncology
drugs in 68 indications. Of the authorised indications for use,
33 were first marketing authorisations and 35 were extensions
(see methods for definitions) Table 1⇓and table A in the
appendix show the approved indication and the date and type
of market authorisation for each agent. Some 58 uses were
granted a regular marketing authorisation, of which seven were
designated as orphan drugs. Ten uses were granted conditional
marketing authorisation (including four designated as orphan
drugs). In total, 11/68 (16%) uses received orphan designation.
Approval for one (bevacizumab in combination with docetaxel
for the treatment of metastatic breast cancer) was subsequently
withdrawn.40
Seventeen drugs were approved for treatment of haematological
malignancies and 51 for treatment of solid tumours. Of these
51, 12 (24%) were for breast cancer, seven (14%) for lung
cancer, five for bowel cancer, and five (10%) for prostate cancer.
Of the 17 drugs approved for treatment of haematological
malignancies, four (24%) were for chronic myeloid leukaemia,
three (18%) for multiple myeloma, and three (18%) for chronic
lymphocytic leukaemia. Most drugs (61/68, 90%) were approved
for use in a non-curative setting (table 1⇓).
Characteristics of pivotal studies
Overall, 72 clinical trials supported the approval of 68 novel
drug uses. Only 18 of the 68 (26%) were supported by a pivotal
study powered to evaluate overall survival as the primary
outcome (table 2⇓ and table B in appendix). Survival was
evaluated as the primary study endpoint in none of the 10
conditionally authorised uses and in only one of the 11 (9%)
with an orphan designation. Overall survival was evaluated as
a primary study endpoint in less than a third (18/58, 31%) of
all drug indications granted regular marketing authorisation.
The remaining drug indications were supported by trials that
evaluated a surrogate measure as the primary study outcome
(table 2⇓ and table B in appendix). This included
progression-free survival for 31 (46%); response rate (including
cytogenetic, haematological, and molecular response rates for
haematological indications) for 11 (16%); disease-free survival
for four (6%); with time to progression, event-free survival,
relapse-free survival, and testosterone concentrations accounting
for the remainder (4/68, 6%).
Just over half (37/68, 54%) of all drug indications had a
supporting pivotal trial evaluating quality of life, but results
were reported for only 35. None of the pivotal trials assessed
quality of life as a primary endpoint (table 2⇓).
Of 68 drug indications, 60 (88%) were supported by at least one
randomised controlled trial, while eight of 68 (12%) were
approved solely on the basis of a single arm study (6/10
indications granted a conditional marketing authorisation and
2/58 granted a regular marketing authorisation) (table 2⇓ and
table B in appendix). Most (6/8, 75%) authorised uses supported
by uncontrolled studies were also orphan designations. On the
other hand, more than half of the orphan drugs in our cohort
(7/11, 64%) were approved on the basis of a randomised trial.
Availability of evidence on overall survival
and quality of life at time of market
authorisation
At time of market approval, according to the EPARs, there was
significant prolongation of survival in just over a third (24/68,
35%) of all drug indications (including 3/17 drugs to treat
haematological malignancies and 21/51 drugs to treat solid
tumours). There were gains in survival for seven compared with
an active comparator, eight compared with placebo, one
compared with best supportive care, and eight as add on
treatment. The magnitude of the overall survival benefit ranged
from 1.0 to 5.8 months (median 2.7 months) (fig 1⇓). For the
44 (65%) remaining drug indications, there was no conclusive
evidence at time of market authorisation that the drugs offered
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survival benefits, either as add on treatment or compared with
placebo or existing treatment options in their authorised use.
There was a significant improvement in quality of life over the
control arm in only seven of the 68 (10%) authorised drug
indications. Five of these were drug indications for which there
was no survival gain at the time of market authorisation, giving
a total of 29 of 68 (43%) that did show improvements in either
quantity or quality of life at time of market entry.
The remaining 39 (57%) drugs had shown no improvement in
survival or quality of life over active treatment, placebo, or as
add on treatment. Eleven were evaluated against an active
comparator, and 10 of these had comparable efficacy with
respect to survival, although in most cases survival data were
immature. Twenty were evaluated against placebo or as add on
treatment and showed no gains in survival or quality of life.
Eight were approved on the basis of a single arm trial.
Availability of evidence on overall survival
and quality of life in postmarketing period
Of the 44 drug indications that did not show a survival benefit
at time of approval, and with a median of 5.4 years’ follow-up
(minimum of 3.3 years and maximum of 8.1 years), three (7%)
were subsequently shown to extend life after market entry and
five (11%) were associated with some improvements in quality
of life (fig 2⇓).
For all three drug indications with a reported survival gain in
the postmarketing period, evidence came from updated analyses
of the pivotal studies supporting initial marketing authorisation,
and all had been granted regular marketing approval. None of
the 10 drugs granted conditional marketing authorisation were
subsequently shown to improve quantity or quality of life. One
of 68 authorised uses judged by the EMA to extend life at time
of market authorisation failed to show such a benefit on longer
follow-up according to the published report.41 Thus, with a
minimum 3.3 years’ follow-up, in 26 of the 68 (38%) authorised
drug indications there was a survival gain (including three of
the seven drugs approved for use in a curative setting).
For the five drug indications with a reported improvement in
quality of life, evidence came from new studies in the same
indicated population with the exception of nilotinib, for which
a published paper42reporting the pivotal study described quality
of life gains not reported in the EPAR. Box 2 lists those drugs
not shown to extend life, but which were associated with a
quality of life benefit with a median of 5.4 years’ follow-up.
Proportion of EMA oncology approvals
meeting ESMO threshold for clinically
meaningful survival benefit
Table 3⇓ shows the ESMO-MCBS scores for all the drugs to
treat solid tumours that showed benefit on overall survival by
the time of our study cut off. After a median of 5.4 years’
follow-up 26 drug indications were associated with a survival
gain, but three of these were for haematological cancers, leaving
a total of 23 to which the ESMO scale could be applied.
Of these 23 drugs, 11 (48%) reached the ESMO threshold for
a meaningful survival benefit; eight out of 20 (40%) for use in
the non-curative setting and all three treatments with curative
intent.
Results summary
Among 68 cancer drug indications approved by the EMA in the
period 2009-13, and with a median of 5.4 years’ follow-up, only
35 (51%) were associated with a significant improvement in
survival (26/35) or quality of life (9/35) over existing treatment
options, placebo, or as add on treatment. Only two of the 26
drugs shown to extend life also showed benefits on quality of
life, and 33 (49%) had not shown any improvement on survival
or quality of life (fig 2⇓). Of the 23 drugs with a survival benefit
that could be scored with the validated ESMO-MCBS tool, only
11 (48%) were judged to offer a clinically meaningful benefit.
Discussion
Summary of findings
This systematic evaluation of oncology drug approvals by the
EMA in 2009-13 shows that most of the drugs (39/68, 57%)
entered the market without evidence of improved survival or
quality of life. At a minimum 3.3 years after market entry, there
was still no conclusive evidence that 33 of these 39 cancer drugs
either extended or improved life. Our findings suggest it is
extremely rare for new studies or follow-up analyses of pivotal
trials in the postmarketing period to report results confirming
that new cancer drugs have a positive impact on the two most
important outcomes for patients—survival and quality of life.
When survival gains over existing treatment options or placebo
were shown, they were often marginal and judged to be
clinically meaningful in less than half (11/23, 48%) of all cases.
What are potential reasons for the paucity of drug approvals
with demonstrable survival advantages over existing treatments?
Firstly, only 18 (26%) indications for use in our cohort were
supported by trials in which extension of life was the primary
outcome, and trials that evaluated survival as a secondary
endpoint might not have been powered to detect differences
between groups with and without the experimental treatment.
Secondly, crossover from control to experimental arm after
disease progression (or to similar drugs after the study) is a
commonly cited reason for the lack of survival benefits in
clinical trials of oncology products.38 It should be noted,
however, that for some indications for use in our cohort there
were no survival gains even in the absence of crossover.7-76
None of the pivotal studies supporting oncology drug approvals
from 2009 to 2013 included quality of life as a primary outcome
measure. This is perhaps unsurprising as the EMA does not
require marketing authorisation holders to evaluate quality of
life, even when drugs are intended for late line palliative care.77
Of the 68 (54%) study indications, 37 were supported by a
pivotal trial in which quality of life was evaluated as a secondary
endpoint, and for only seven (10%) was there a significant
improvement in quality of life at time of market entry. Neither
the EPARs nor the published studies were consistent in reporting
whether significant improvements for specific quality of life
outcomes were also clinically relevant. These are particularly
troubling findings as many of the drugs in our sample were
approved to treat advanced metastatic disease, when the purpose
of treatment is palliative—that is, to improve quality of life—or
to extend life while ensuring that any survival gains are not
outweighed by a deterioration in quality of life from adverse
events or other negative factors related to treatment.78 79
A significant minority of drugs in our sample (8/68, 12%) were
approved solely on the basis of a single arm study. Most of the
indications supported by single arm studies (6/8) were granted
orphan designation, and it is recognised that the conduct of
randomised trials to investigate treatments for rare cancers can
be challenging. Nevertheless, a review of FDA approvals
indicates that randomised controlled trials are feasible even in
rare cancers with an incidence of less than 1/100 000/year.80
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Box 1: Abbreviations used in tables and figures
5FU=5 fluorouracil; adenoca=adenocarcinoma; AI=aromatase inhibitor; ALCL=anaplastic large cell lymphoma; ALK=anaplastic lymphoma
kinase; ALL=acute lymphoblastic leukaemia; AML=acute myeloid leukaemia; AP=accelerated phase; ASCT=autologous stem cell transplant;
BC=breast cancer; BCC=basal cell carcinoma; BP=blast phase; chemo: BCS=best supportive care; chemo=chemotherapy; CLL=chronic
lymphocytic leukaemia; CML=chronic myelogenous leukaemia; CP=chronic phase; EFGR=epidermal growth factor receptor; EGFRi=epidermal
growth factor receptor inhibitor; FOLFIRI: irinotecan/5 fluorouracil/folinic acid; FOLFOX: oxaliplatin/5 fluorouracil/folinic acid; GC=gastric
cancer; GIST=gastrointestinal stromal tumours; HL=Hodgkin lymphoma; HR=hormone receptor; mBC=metastatic breast cancer; MCL=mantle
cell lymphoma; mCRC=metastatic colorectal cancer; mCRPC=metastatic castration resistant prostate cancer; mGC=metastatic gastric
cancer; mGOJ=metastatic gastric or esophageal junction; mNSCLC=metastatic non-small cell lung cancer; mPC=metastatic prostate cancer;
mut=mutation; non-squam=non-squamous; PBO=placebo; NHL=non-Hodgkin lymphoma; NR=not reported; PC=prostate cancer;
Ph+=Philadelphia chromosome positive; PLD=pegylated liposomal doxorubicin; PNET=pancreatic neuroendocrine tumours; pred=prednisone
or prednisolone; RCC=renal cell carcinoma; SCT=stem cell transplantation; squam=squamous; STS=soft tissue sarcoma; TC=thyroid cancer;
TCC=transitional cell carcinoma; TKI=tyrosine kinase inhibitor; VEGFi=vascular endothelial growth factor inhibitor; WT=wild-type
Box 2: Cancer drugs associated with benefit on health related quality of life (HRQoL)
Reported at time of market approval
• Afatinib v pemetrexed/cisplatin (for the treatment of TKI-naive, EGFR mutation +ve, non-small cell lung cancer) significantly delayed
the time to deterioration for cough and dyspnoea but not time to deterioration of pain. HRQoL was evaluated against prespecified
components of the European Organisation for Research and Treatment of Cancer quality of life questionnaire C30 (EORTC QLQ-C30)
questionnaire and lung cancer module QLQ-LC13. The study was open label43
• Gefitnib (for the treatment of metastatic non-small cell lung cancer) showed significant benefits on quality of life compared with
carboplatin plus paclitaxel, and with docetaxel on some measures, but not compared with placebo. HRQoL was assessed with the
functional assessment of cancer therapy-lung (FACT-L), and trial outcome index (TOI), and symptom improvement by the lung cancer
subscale (LCS). The active comparator trials were open label. The trial v placebo was double blind44
• Tegafur, gimeracil, oteracil (S-1) (in combination with cisplatin for the treatment of advanced gastric cancer) showed a significant
improvement over cisplatin/5-fluorouracil for only one of the subscales (physical wellbeing) of the functional assessment of cancer
therapy-gastric (FACT-Ga) HRQOL instrument. The study was open label45
• Vandetanib v placebo (for the treatment of metastatic medullary thyroid cancer) significantly improved “time to worsening of pain” (a
composite endpoint based on patient reported analgesic use and responses to the brief pain inventory) but did not show a significant
improvement for the functional assessment of cancer therapy-general (FACT-G) score. The study was double blind46
Reported in the postmarketing period
• Crizotinib (for second line treatment of ALK mutation +ve advanced non-small cell lung cancer) showed significant improvements
compared with pemetrexed across a range of HRQoL measures, including a significantly greater delay in time to worsening of
symptoms. HRQoL was assessed with the European Organisation for Research and Treatment of Cancer quality of life questionnaire
C30 (EORTC QLQ-C30) and the lung cancer module QLQ-LC13. The study was open label47
• Erlotinib (for first line treatment of EGFR mutation +ve metastatic non-small cell lung cancer) showed clinically relevant and significant
improvements compared with gemcitabine/carboplatin in total functional assessment of cancer therapy-lung (FACT-L), trial outcome
index (TOI), and lung cancer subscale (LCS) scores. The study was open label48
• Nilotinib v imatinib (for patients with newly diagnosed Ph+ chronic myeloid leukaemia) reported a significant quality of life improvement
with respect to some categories of low grade adverse events. HRQoL was assessed with generic SF-36 and leukaemia specific
functional assessment of cancer therapy-leukaemia (FACT-Leu) surveys. The study was open label42
• Ofatumumab (in patients with chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab) showed significant
improvements v “physician’s choice” with respect to fatigue but not side effects of treatment or effects of disease. HRQoL was evaluated
according to three prespecified domains of the European Organisation for Research and Treatment of Cancer Quality of Life
Questionnaire C30 (EORTC-C30) and the chronic lymphocytic leukaemia module QLQ-CLL16 (fatigue, side effects of treatment, and
effects of disease). The study was open label49
• Pazopanib (for first line treatment of advanced renal cell carcinoma) significantly improved HRQoL compared with sunitinib with respect
to 11 of 14 HRQoL domains. HRQoL was assessed with the functional assessment of chronic illness therapy-fatigue (FACIT-F)
questionnaire, the National Comprehensive Cancer Network/functional assessment of cancer therapy-kidney symptom index 19
(NCCN-FACT FKSI-19), and the cancer therapy satisfaction questionnaire. The study was open label50
Comparison with other studies
Apolone and colleagues27 evaluated the evidence base for new
cancer drugs approved by the EMA in the period 1995-2004.
In that 10 year period the EMA authorised 14 anticancer drugs
for 27 indications. An important difference between their earlier
study and the present one is that the earlier cohort includes only
drugs to treat solid tumours. Nevertheless, our findings indicate
some improvements in the quality of the evidence base
supporting new oncology drugs. For example, drug uses
authorised in the study period 2009-13 were more likely to be
supported by trials that included overall survival as a primary
endpoint (26% v 8%), and by randomised trials (88% v 66%).
There has been a substantial increase in the number of approved
treatments for solid tumours compared with the earlier
period—an average of 12 a year for 2009-20 compared with
three a year for 1995-2004.
In contrast with recent studies focusing on a subset of oncology
drug approvals in Europe,32 33 we included all authorised
oncology indications regardless of route of approval and
systematically analysed survival and quality of life benefits.
We also relied exclusively on evidence generated from
randomised controlled trials. We did not therefore accept
mathematical models considered by health technology
assessment bodies such as the National Institute for Health and
Care Excellence.81 There is continuing debate around the validity
of simulation models that extrapolate findings from short term
trials.82 83 Our analysis is the first to investigate whether drugs
that did not show a survival benefit at the time of approval in
Europe are subsequently shown to improve survival or quality
of life in follow-up randomised controlled trials once drugs are
on the market.
Study limitations
There are several limitations to this study. Firstly, there were
several cases in which results reported in the EPARs were
ambiguous or incomplete. When difficulties in interpretation
occurred, we ensured our determinations were consistent with
the EMA’s conclusions. Following this approach, we determined
that significant survival benefits had been shown at time of
market authorisation for vinflunine (in transitional cell
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carcinoma) and trastuzumab (in neoadjuvant breast cancer),
despite uncertainty regarding the reported statistical analyses.
When the EMA’s opinions on specific questions were not clear
or not available, we adopted a generous approach that favoured
the drug. For example, we credited panitumumab with showing
a survival benefit in the postmarketing period on the basis of
an “exploratory” analysis.84
There was also considerable variation in the reporting of quality
of life endpoints in both the EPARs and the medical literature.
Significant results might have been shown for isolated
parameters or single subscales only, and it was not clear whether
a net quality of life benefit had been shown. Nor was it
consistently reported whether or not the magnitude of
improvement was such that it would be considered clinically
meaningful for patients. Consequently, we might have
overestimated the proportion of drugs that offer benefits on
survival or quality of life and the clinical meaningfulness of
these. Our findings, however, are consistent with recent findings
from the US.30 85
Secondly, we did not consider the appropriateness of clinical
trial design, including whether a treatment administered in the
control arm of a study was optimal or even informative. This
is an important study limitation, which again means we might
have overestimated the benefits offered by the drugs in our
sample. For example, the control arm of the pivotal trial to
support approval of ipilimumab for metastatic melanoma was
an experimental treatment. Similarly, the pivotal trial to support
lapatinib in combination with trastuzumab for patients with
metastatic breast cancer used lapatinib monotherapy as the
comparison—a treatment acknowledged in the EPAR to be
“without established efficacy.”86 Although this trial design failed
to isolate the effects of the test drug, the EMA nevertheless
concluded that the reported benefit in survival was clinically
relevant and could be attributed to the combination.
Thirdly, our ESMO ratings share the limitations of the published
studies on which they are based. For example, the magnitude
of clinical benefit shown in a particular trial could be inflated
by the choice of an inappropriate comparator or treatment in
the control arm that does not represent best standard of care.38
Several maintenance therapy trials for metastatic non-small cell
lung cancer, for example, have been criticised for flawed study
designs that systematically result in substandard care in the
control arms.87 In the case of lapatinib combined with
tratuzumab, the pivotal study was scored 4 on the basis of a 4.5
month survival gain over lapatinib monotherapy (with no
established efficacy).
Fourthly, our findings do not reflect the totality of the evidence
base for a specific authorised indication as we did not take
account of studies with negative results for the same drug
indication if they were not reported as pivotal studies in the
EPAR, nor did we take account of the fact that studies with
positive results for a particular indication could conflict with
negative findings from other studies in the same indicated patient
population.
Implications for clinical practice and
regulatory policy
Despite the EMA’s statement that overall survival is the “most
persuasive outcome” for studies investigating the clinical safety
and efficacy of new oncology drugs and new uses of such drugs,
European regulators commonly accept the use of surrogate
measures of drug benefit as primary endpoints in pivotal trials
for both conditional and regular pathways to market
authorisation.11 88 In addition, any demonstration of a statistically
significant difference in survival between treatments, however
small and regardless of whether such a difference is clinically
meaningful to patients, has recently been accepted as the basis
for approving new cancer drugs.89 To a large extent, regulatory
evidence standards determine the clinical value of, and the
quality of the evidence base for, new oncology drugs. Our study
suggests these standards are failing to incentivise drug
development that best meets the needs of patients, clinicians,
and healthcare systems.15-21
Though surrogate endpoints are argued to have the advantage
of allowing quicker drug development and patient access, it is
questionable whether studies based on surrogate measures of
efficacy provide optimal, or even meaningful, information for
patients and clinicians.24 Moreover, our analysis raises the
possibility that regulatory and current research practices have
created a situation in which critical information about the
outcomes that matter most to patients might never be generated
once oncology drugs are approved for widespread use. The
limited availability of studies showing either benefits to overall
survival or quality of life in the postmarketing period
underscores the importance of requiring robust evidence of
clinical benefit at the time of marketing authorisation.90-92
The EMA and other drug regulatory agencies should reconsider
when, and to what extent, it is appropriate to approve new cancer
drugs on the basis of surrogate endpoints. Furthermore, when
gains in survival and quality of life are shown, these gains should
be meaningful to patients and clinicians.
Conclusion
Among 68 cancer drug indications approved by the EMA in the
period 2009-13, and with a median of 5.4 years’ follow-up, only
35 (51%) were associated with significant improvement in
survival or quality of life over alternative treatment options,
placebo, or as add on treatment. For 33 (49%), uncertainty
remains over whether the drugs extend survival or improve
quality of life. Of the 23 drugs with a survival benefit that could
be scored with the validated ESMO-MCBS tool, only 11 (48%)
were judged to offer a clinically meaningful benefit.
Most new oncology drugs authorised by the EMA in 2009-13
came onto the market without clear evidence that they improved
the quality or quantity of patients’ lives, and, when survival
gains over available treatment alternatives were shown, they
were not always clinically meaningful. Little new information
to guide patients, their treating clinicians, or decisions about
whether or not to pay for treatments was generated in the
postmarketing period. This situation has negative implications
for patients and public health.19 93 When expensive drugs that
lack clinically meaningful benefits are approved and paid for
within publicly funded healthcare systems, individual patients
can be harmed, important societal resources wasted, and the
delivery of equitable and affordable care undermined.
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Tables
Table 1| Characteristics of approvals of cancer drug, 2009-13. Figures are numbers (percentage) of indications
Haematological tumours (n=17)Solid tumours (n=51)Characteristics
Type of marketing authorisation:
9 (53)24 (47)  First marketing authorisation
8 (47)27 (53)  Extension
Pathway of first marketing authorisation:
4 (44)19 (79)  Regular approval
5 (56)5 (21)  Conditional approval
8 (47)3 (6)  Orphan designation
Intent of treatment:
1 (6)6 (12)  Curative
16 (94)45 (88)  Non-curative
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Table 2| Characteristics of pivotal trials of cancer drugs. Figures are numbers (percentage) unless stated otherwise
Haematological tumours (n=18)Solid tumours (n=54)Characteristics
Pivotal trial design:
13 (72)52 (96)  Randomised trial
5 (28)2 (4)  Single arm trial
Comparator:
9 (50)15 (28)  Active
0 (0)25 (46)  Placebo
4 (22)12 (22)  Add on
5 (28)2 (4)  None
1 (6)18 (33)  OS as primary endpoint
17 (94)47 (87)  OS or QoL as secondary endpoint
484 (58-1018)696 (96-3222)  Median (range) sample size
OS=overall survival; QoL=quality of life.
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Table 3| ESMO grades for 23 drugs used to treat solid tumours that showed benefit on overall survival after follow-up
ESMO
score‡
QoL/toxicity†HR (CI)Overall
survival
gain*
TrialIndicationSiteDrugStudy
4Yes0.74 (0.64 to
0.86)
4.6COU-AA-301
(prednisone±abiraterone)
mCRPC (+pred) after
chemo
ProstateAbirateroneFizazi (2012)51
4Yes0.81 (0.70 to
0.93)
4.4COU-AA-302
(abiraterone+prednisone or
prednisolone v placebo+prednisone
or prednisolone)
mCRPC (+pred) before
chemo
ProstateAbirateroneRyan (2015)52
1No0.817 (0.713 to
0.937)
1.44VELOUR (aflibercept, then FOFIRI v
placebo, then FOLFIRI)
2nd line mCRC
(+FOLFIRI)
BowelAfliberceptVan Cutsem
(2012)53
2No0.70 (0.59 to
0.83)
2.4TROPIC (cabazitaxel+prednisone or
prednisolone v
mitoxantrone+prednisone or
prednisolone)
Hormone refractory mPC
(+pred) previously treated
with docetaxel
ProstateCabazitaxelDe Bono
(2010)54
2No0.81 (0.66 to
0.99)
2.5EMBRACE (eribulin v physician’s
choice)
3rd line mBCBreastEribulinCortes
(2011)55
1No0.81 (0.70 to
0.95)
1SATURN (erlotinib v placebo)Maintenance therapy in
mNSCLC (previous
platinum based chemo)
LungErlotinibCappuzzo
(2010)56
4Yes0.63 (0.53 to
0.75)
4.8AFFIRM (enzalutamide v placebo)mCRPC after docetaxelProstateEnzalutamideScher (2012)57
4No0.66 (0.51 to
0.87)
3.7MDX010-20 (ipilimumab v vaccine
alone)
2nd line unresectable or
metastatic melanoma
SkinIpilimumabHodi (2010)58
2No0.72 (0.59 to
0.87)
2.1CA184-024 (dacarbazine±ipilimumab)1st line unresectable or
metastatic melanoma
SkinIpilimumabRobert
(2011)59
4No0.74 (0.57 to
0.97)
4.5EGF104900 (lapatinib±trastuzumab)HER2+ HR- mBC (+
trastuzumab). Previous
trastuzumab + chemo
BreastLapatinibBlackwell
(2012)60
ANR0.71 (0.52 to
0.96)
6 years;
8%
INT-0133Resectable,
non-metastatic
osteosarcoma after
complete resection (+
chemo)
OsteosarcomaMifamurtideMeyers
(2008)61
2No0.72 (0.62 to
0.83)
2.1CA046 (gemcitabine±nab-paclitaxel)1st line (+ gemcitabine)
metastatic pancreatic
adenoca
PancreaticNab-paclitaxelGoldstein
(2015)62
3No0.83 (0.70 to
0.98)
4.4PRIME (FOLFOX4±panitumumab)1st line KRAS WT mCRC
(+ FOLFOX)
BowelPanitumumabDouillard
(2014)63
3No0.79 0.65 to
0.95)
2.8JMEN (pemetrexed+BSC v
placebo+BSC)
Maintenance for
mNSCLC (non-squam)
after platinum based
doublet chemo
(w/gemcitabine or
taxane)
LungPemetrexedCiuleanu
(2009)64
3No0.78 (0.64 to
0.96)
2.9PARAMOUNT (pemetrexed+BSC v
placebo+BSC)
Maintenance for
mNSCLC (non-squam)
after platinum based
chemo
LungPemetrexedPaz-Ares
(2013)65
4No0.68 (0.56 to
0.84)
15.7CLEOPATRA
(trastuzumab+chemo±pertuzumab)
1st line HER2+ mBCBreastPertuzumabSwain
(2015)66
1No0.77 (0.64 to
0.94)
1.4CORRECT (regorafenib v placebo)mCRC either after
previous treatment
with/or ineligible for
5FU-based chemo or
VEGFi or EGFRi therapy
BowelRegorafenibGrothey
(2013)67
3No0.74 (0.60 to
0.91)
2.7ToGA (5-FU or
capecitabine+cisplatin±trastuzumab)
1st line HER2+ mGC or
mGOJ adenoca
StomachTrastuzumabBang (2010)68
ANR0.63 (0.54 to
0.73)
10 years;
8.8%
NASBP-31 and NCCTG-N9831
(doxorubicin+cyclophosphamide,
followed by paclitaxel±trastuzumab)
HER2+ BC (+taxane)
after adjuvant chemo
BreastTrastuzumabPerez (2014)69
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Table 3 (continued)
ESMO
score‡
QoL/toxicity†HR (CI)Overall
survival
gain*
TrialIndicationSiteDrugStudy
BNo0.63 (NR)5.4
years;
5%
BCIRG-006
(doxorubicin+cyclophosphamide,
followed by trastuzumab v
HER2+ BC (+adjuvant
chemo)
BreastTrastuzumabSlamon
(2011)70
doxorubicin+cyclophosphamide,
followed by docetaxel)
5Yes0.68 (0.55 to
0.85)
5.8EMILIA (trastuzumab emanstine v
lapatinib+capecitabine)
HER2+ unresectable or
mBC after trastuzumab
and/or taxane
BreastTrastuzumab
emtansine
Verma
(2012)71
4No0.70 (0.57 to
0.87)
3.9BRIM-3 (vemurafenib v dacarbazine)Unresectable or
metastatic melanoma
(BRAF V600 mut)
SkinVemurafenibMcArthur
(2014)72
3No0.77 (0.61 to
0.99)
2.6VFL-302 (vinflunine+BSC v BSC)Advanced or metastatic
TCC of urothelial tract.
Previous platinum
regimen
UrinaryVinflunineBellmunt
(2009)73
See box 1 for abbreviations.
*Survival gain in months, or percent of patients surviving at x years.
†Yes=quality of life or improved toxicity reported; no=no quality of life gain or improvement in toxicity reported, or toxicity might be worse.
‡For drug indications with curative intent, grade of A or B indicates trial data show drug offers clinically meaningful benefit. For drug indications with non-curative
intent, grade of 4 or 5 indicates trial data show drug offers clinically meaningful benefit. For drugs with non-curative intent, grade of 1, 2, or 3 indicates drug does
not reach ESMO threshold for clinically meaningful benefit.
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Figures
Fig 1 Magnitude of overall survival benefit at the time of EMA approval. Figure excludes seven indications for which median
overall survival could not be estimated at time of marketing authorisation: mifamurtide for resectable non-metastatic
osteosarcoma after complete resection (+chemo); pertuzumab for 1st line HER2+mBC; pomalidomide for 3rd line
(+dexamethasone) relapsed and refractory multiple myeloma; rituximab for 1st line CLL (+chemo); trastuzumab for HER2+
BC (+taxane) after adjuvant chemo; trastuzumab for HER2+BC (+adjuvant chemo); and trastuzumab for HER2+locally
advanced BC (+neoadjuvant chemo and as monotherapy adjuvantly). Box 1 shows abbreviations used
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Fig 2 Availability of benefits on overall survival and quality of life of cancer drugs approved 2009-13. Box 1 shows
abbreviations used
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